Drug Approval | December 08, 2023
Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Approval to dramatically change CAR-T therapies landscape
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
_256_384.jpeg)
Launched Pathology Laboratory in Vijayawada offering a wide range of best-in-class diagnostic services with over 2500+ tests
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
Continues to Expand its Presence in South India
Subscribe To Our Newsletter & Stay Updated
